RESUMO
In 3 patients with ANLL, chemotherapy including high or conventional doses of Ara-C had been ineffective. However subsequent treatment with low-dose (LD) Ara-C induced a PR or CR which were sustained with regular LD Ara-C reinduction courses. Survival of the 2 patients with PR was 24 and 8 months respectively. The patient with CR was alive 18 months after a bone marrow graft. In 2/3 cases, the cytogenetic abnormalities initially detected disappeared with treatment. These observations suggest that the cellular mechanism of action of LD Ara-C is different from that of HD Ara-C, but do not favour a differentiating action of LD Ara-C. LD Ara-C can be prescribed as a salvage therapy even after failure of high or conventional doses.
Assuntos
Citarabina/uso terapêutico , Leucemia Mieloide Aguda/tratamento farmacológico , Adulto , Medula Óssea/patologia , Transplante de Medula Óssea , Criança , Terapia Combinada , Citarabina/administração & dosagem , Relação Dose-Resposta a Droga , Feminino , Humanos , Leucemia Mieloide Aguda/patologia , Leucemia Mieloide Aguda/cirurgia , Leucemia Mielomonocítica Aguda/tratamento farmacológico , Masculino , Pessoa de Meia-Idade , Indução de RemissãoRESUMO
The Coulter Counter S + II is one of the most frequently used automatic counter in France. The authors evaluated its performances by analysing 116 blood samples from newborn infants aged less than one month. The reliability of this counter is impaired by the numerous rejects of lymphocytes or platelets and by the failure to recognize erythroblasts or circulating immature granulocytes. Moreover, abnormal cellular populations are notified which sometimes do not appear to be linked to any clinical disorder and are not evidenced by microscope examination control. These constatations bound the utilisation of this counter at least as far as the newborn's hematology is concerned.
